With further regulatory validation, screening for BRCA1 c.68_69del, BRCA1 c.5266dup and BRCA2 c.5946del mutations by Sanger sequencing can be performed at an affordable cost in conjunction with Pap smear cytology and HPV assays for evaluation of the risks of cervical cancer, ovarian cancer and breast cancer among selective patients. This evidence concerns the gene BRCA2 and breast carcinoma.